Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Saturday. The firm issued a sell rating on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $2.00 price target on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Stock Performance

SENS opened at $0.35 on Friday. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17. Senseonics has a 12-month low of $0.32 and a 12-month high of $0.75. The firm has a 50 day moving average of $0.40 and a two-hundred day moving average of $0.44. The firm has a market capitalization of $183.69 million, a PE ratio of -2.47 and a beta of 0.79.

Senseonics (NYSE:SENS) last issued its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The firm had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.86 million. On average, analysts anticipate that Senseonics will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Senseonics

Several institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC increased its position in shares of Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Senseonics during the first quarter worth about $162,000. Price T Rowe Associates Inc. MD raised its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Senseonics in the 1st quarter worth about $91,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.